Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists probe brain chemistry to unlock thinking problems in schizophrenia

NCT ID NCT07162467

Knowledge-focused Sponsor: Tianjin Anding Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study looks at how a specific brain chemical pathway (tryptophan-kynurenine) relates to thinking and memory problems in people with schizophrenia. Researchers will measure blood levels of these chemicals and assess cognitive function in 200 participants, including healthy volunteers. The goal is to find early markers of cognitive impairment and identify potential targets for future treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could point toward new treatments for cognitive problems in schizophrenia and help identify thinking issues earlier.
What could go wrong
This is an observational study, not a treatment trial. It may not lead directly to new therapies, and results may not apply to all people with schizophrenia.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2024

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study will recruit 100 Han Chinese adults aged 18-55 years for two cohorts: patients and healthy controls. The patient cohort will comprise individuals experiencing their first episode of schizophrenia or schizophreniform disorder with a duration of ≤ 5 years, who have either never received antipsychotic treatment or have received it for a cumulative duration of ≤ 4 weeks prior to enrollment. Recruitment will be conducted from the outpatient and inpatient services of Tianjin Anding Hospital and surrounding communities in Tianjin, China. The healthy control cohort will consist of 100 Han Chinese adults matched to the patient group for sex, age, and education. These individuals must have no personal or family history of major psychiatric disorders and demonstrate no cognitive impairment on formal testing.

Ages

18 to 55 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Healthy volunteers matched to the patient group on sex, age, and education level; * Ethnic Han Chinese; * Able and willing to provide written informed consent. Exclusion Criteria: * Significant comorbid medical or neurological conditions; * Any DSM-5-defined psychiatric disorder; * Family history of psychiatric illness spanning three or more generations; * Current use of psychoactive medications; * Refusal to provide informed consent/participate.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Schizophrenia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Schizophrenia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Tianjin Anding Hospital

    Tianjin, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.